Risk of cardiovascular involvement in pediatric patients with X-linked hypophosphatemia
- PMID: 30607568
- DOI: 10.1007/s00467-018-4180-3
Risk of cardiovascular involvement in pediatric patients with X-linked hypophosphatemia
Abstract
Objective: To find out if cardiovascular alterations are present in pediatric patients with X-linked hypophosphatemia (XLH).
Study design: Multicentre prospective clinical study on pediatric patients included in the RenalTube database ( www.renaltube.com ) with genetically confirmed diagnosis of XLH by mutations in the PHEX gene. The study's protocol consisted of biochemical work-up, 24-h ambulatory blood pressure monitoring (ABPM), carotid ultrasonography, and echocardiogram. All patients were on chronic treatment with phosphate supplements and 1-hydroxy vitamin D metabolites.
Results: Twenty-four patients (17 females, from 1 to 17 years of age) were studied. Serum concentrations (X ± SD) of phosphate and intact parathyroid hormone were 2.66 ± 0.60 mg/dl and 58.3 ± 26.8 pg/ml, respectively. Serum fibroblast growth factor 23 (FGF23) concentration was 278.18 ± 294.45 pg/ml (normal < 60 pg/ml). Abnormally high carotid intima media thickness was found in one patient, who was obese and hypertensive as revealed by ABPM, which disclosed arterial hypertension in two other patients. Z scores for echocardiographic interventricular septum end diastole and left ventricular posterior wall end diastole were + 0.77 ± 0.77 and + 0.94 ± 0.86, respectively. Left ventricular mass index (LVMI) was 44.93 ± 19.18 g/m2.7, and four patients, in addition to the obese one, had values greater than 51 g/m2.7, indicative of left ventricular hypertrophy. There was no correlation between these echocardiographic parameters and serum FGF23 concentrations.
Conclusions: XLH pediatric patients receiving conventional treatment have echocardiographic measurements of ventricular mass within normal reference values, but above the mean, and 18% have LVMI suggestive of left ventricular hypertrophy without correlation with serum FGF23 concentrations. This might indicate an increased risk of cardiovascular involvement in XLH.
Keywords: FGF23; Intima-media of carotid artery; Left ventricular hypertrophy; PHEX gene; XLH.
Similar articles
-
Reassuring Data on the Cardiovascular Risk in Adults With X-linked Hypophosphatemia Receiving Conventional Therapy.J Clin Endocrinol Metab. 2024 Jan 18;109(2):e488-e494. doi: 10.1210/clinem/dgad608. J Clin Endocrinol Metab. 2024. PMID: 37843399
-
High iFGF23 level despite hypophosphatemia is one of the clinical indicators to make diagnosis of XLH.Endocr J. 2011;58(8):647-55. doi: 10.1507/endocrj.k10e-257. Epub 2011 May 19. Endocr J. 2011. PMID: 21597229
-
Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations.J Clin Endocrinol Metab. 2010 Apr;95(4):1846-50. doi: 10.1210/jc.2009-1671. Epub 2010 Feb 15. J Clin Endocrinol Metab. 2010. PMID: 20157195 Free PMC article. Clinical Trial.
-
FGF23 and its role in X-linked hypophosphatemia-related morbidity.Orphanet J Rare Dis. 2019 Feb 26;14(1):58. doi: 10.1186/s13023-019-1014-8. Orphanet J Rare Dis. 2019. PMID: 30808384 Free PMC article. Review.
-
X-linked hypophosphatemia and growth.Rev Endocr Metab Disord. 2017 Mar;18(1):107-115. doi: 10.1007/s11154-017-9408-1. Rev Endocr Metab Disord. 2017. PMID: 28130634 Review.
Cited by
-
Whole exome sequencing identifies two novel variants in PHEX and DMP1 in Malaysian children with hypophosphatemic rickets.Ital J Pediatr. 2022 Dec 8;48(1):193. doi: 10.1186/s13052-022-01385-5. Ital J Pediatr. 2022. PMID: 36482408 Free PMC article.
-
Fibroblast growth factor 23-Klotho and hypertension: experimental and clinical mechanisms.Pediatr Nephrol. 2021 Oct;36(10):3007-3022. doi: 10.1007/s00467-020-04843-6. Epub 2020 Nov 23. Pediatr Nephrol. 2021. PMID: 33230698 Free PMC article. Review.
-
FGFR4 Is Required for Concentric Growth of Cardiac Myocytes during Physiologic Cardiac Hypertrophy.J Cardiovasc Dev Dis. 2024 Oct 12;11(10):320. doi: 10.3390/jcdd11100320. J Cardiovasc Dev Dis. 2024. PMID: 39452290 Free PMC article.
-
FGF23 and klotho at the intersection of kidney and cardiovascular disease.Nat Rev Cardiol. 2024 Jan;21(1):11-24. doi: 10.1038/s41569-023-00903-0. Epub 2023 Jul 13. Nat Rev Cardiol. 2024. PMID: 37443358 Review.
-
The Complexity of FGF23 Effects on Cardiomyocytes in Normal and Uremic Milieu.Cells. 2021 May 20;10(5):1266. doi: 10.3390/cells10051266. Cells. 2021. PMID: 34065339 Free PMC article. Review.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources